 |
(NaturalNews) What investors had hoped would build into yet another 2.68 percent dividend yield for pharmaceutical behemoth Eli Lilly has turned into a massive financial letdown after trials of solanezumab, a supposedly promising experimental drug for Alzheimer’s disease and other forms of dementia, showed less than favorable efficacy in the latest clinical trials. Reports indicate... |
from NaturalNews.com http://ift.tt/2hPraHD
No comments:
Post a Comment